Jack Arnold and Rihards Buss preview 6 ACR 2026 abstracts spanning ICI arthritis, PsA proteomics, JAK inhibitor prescribing, and B-cell depletion.
|Articles|August 14, 2013
Leg Pain and Weakness in a 22-Year-Old Woman
This case and a bonus set of images from another woman with the same diagnosis reveal some of the many manifestations of her condition. Can you guess her diagnosis?
Advertisement
A radiologist notes high signal on the inversion recovery sequence in this MRI image from a young woman with pain and weakness in her lower extremities.
What do you see in the image?
Can you guess what other body structures than her muscles are also involved?
To learn the diagnosis and see radiological images from an older woman with the same condition, click here to read the
Advertisement
Related to this article
The FDA approved tildrakizumab for adults with active psoriatic arthritis based on two phase 3 trials showing improved ACR20 response at week 24 vs placebo.
Buss and Arnolds discuss underscore persistent gaps between gout guideline recommendations and real-world practice.
Jessica Gordon, MD, MS, and New York rheumatologists discuss who to screen for ILD, how to monitor without overimaging, and when to add antifibrotics.
Koji Ishikawa, MD, PhD, emphasized that 12 months of romosozumab showed benefits for osteoporosis.
On World Arthritis Day, TOGETHER-PsA data and 3 rheumatology/derm experts frame GLP-1 agonists as a promising — but not yet proven — adjunct therapy.
At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Advertisement
Advertisement